Cutaneous ulcers due to interferon seem not to be related to the dosage.
Virgili
A
A
Corazza
M
M
Lombardi
A R
AR
Sighinolfi
L
L
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology; D012883:Skin Ulcer / Q000139:chemically induced* / Q000473:pathology; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015215:Zidovudine